| Basics |
Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a US-based biopharmaceutical company. The firm is engaged primarily in developing medicines for patients suffering with rare neurological disorders.
|
| IPO Date: |
May 10, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$118.92M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.13 | 3.39%
|
| Avg Daily Range (30 D): |
$0.07 | 4.53%
|
| Avg Daily Range (90 D): |
$0.07 | 5.38%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.53M |
| Avg Daily Volume (30 D): |
1.59M |
| Avg Daily Volume (90 D): |
2.19M |
| Trade Size |
| Avg Trade Size (Sh.): |
210 |
| Avg Trade Size (Sh.) (30 D): |
370 |
| Avg Trade Size (Sh.) (90 D): |
333 |
| Institutional Trades |
| Total Inst.Trades: |
114 |
| Avg Inst. Trade: |
$2.12M |
| Avg Inst. Trade (30 D): |
$.6M |
| Avg Inst. Trade (90 D): |
$.58M |
| Avg Inst. Trade Volume: |
.56M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.45M |
| Avg Closing Trade (30 D): |
$1.44M |
| Avg Closing Trade (90 D): |
$1.44M |
| Avg Closing Volume: |
821.93K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
|
|
|
Diluted EPS
|
|
|
|
|
Revenue
|
$ 6.61M
|
$ .13M
|
$
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -36.33M
|
$ -12.16M
|
$ -4.68M
|
|
Operating Income / Loss
|
$ -40.87M
|
$ -12.52M
|
$
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 5.59M
|
$
|
$
|
|
PE Ratio
|
|
|
|
|
|
|
